Jazz Pharmaceuticals Stock News

ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates. Post the announcement, the share price rises.

Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.

Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he increased his stake in IDEAYA Biosciences Inc. ( IDYA , Financial) by 52.12%.

LOS ANGELES (AP) — Anthony Davis left the Los Angeles Lakers'' game Wednesday night against the Utah Jazz after badly rolling his right ankle during the second quarter. Davis was down on the court for several minutes after the injury. Davis went up to catch a lob pass and came down on Rudy Gobert''s heel with 3 minutes remaining in the first half. Davis was unable to put any weight on his right foot and had to be helped off the court by teammates DeAndre Jordan and Dwight Howard into the locker room. Davis — averaging 23.3 points and 9.1 rebounds — missed 17 games this season due to a knee injury. He was averaging 23.2 points and 10.1 rebounds in the nine games since his return. He was off to another strong start against the Jazz with 17 points in 17 minutes before his injury. It is another bad break for the Lakers, who came into the game on a three-game losing streak. Los Angeles (26-31) is a season-high five games under .500 and in ninth place in the Western Conference. Wednesday also marked only the sixth time since Dec.

Q4 2021 Key Metrics Net income of $10.2 million , or $0.06 per basic share; a quarter-over-quarter increase of $1.0 million primarily due to lower impairment and expected credit loss provisions of $31.0 million in the Regional Aircraft Leasing (''RAL'') segment in addition to increased revenue in the Regional Aviation Services (''RAS'') segment, partially offset by a reduction in unrealized foreign exchange gains of $35.4 million . Adjusted net income 1 of $21.5 million , or $0.12 per basic share; an increase of $13.8 million quarter-over-quarter primarily due to additional aircraft earning leasing revenue, lower depreciation, and a reduction in realized foreign exchange losses. Adjusted EBITDA 1 of $90.5 million ; an increase of $8.5 million over fourth quarter 2020 due to additional aircraft earning leasing revenue and a lower expected credit loss provision partially offset by decreased earnings due to a lower US dollar exchange rate. Collected approximately 83% (67% in Q2''21, 77% in Q3''21) of the RAL segment''s lease revenue recognized in the fourth quarter.

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Let's see if Jazz Pharmaceuticals plc (JAZZ) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.

Jazz Pharmaceuticals' 2025 Vision Seems Optimistic

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.